ActiveSite Pharmaceuticals’ Small Molecule Protease Inhibitor Blocks Retinal Blood Vessel Damage In Rodent Model Of Diabetes
ActiveSite Pharmaceuticals, Inc., announced today the online publication of a study in the journal Diabetes that describes the effectiveness of its novel plasma kallikrein inhibitor ASP-440 in reducing blood-retinal barrier breakdown in a rodent model of diabetes...